Australia’s ongoing efforts to restrict its medical cannabis market, now the largest outside North America, are now taking aim at the special access scheme (SAS) framework on which the country’s hundreds of thousands of annual prescriptions are based.
As Europe’s medical cannabis market matures, a new category of operator is beginning to emerge.
As the European cannabis conference season gets started, industry experts, lawmakers, regulators and business owners are facing greater mainstream scrutiny than ever before.
The UK and Germany’s medical cannabis markets both more than doubled in size throughout 2025, once again cementing the countries as the engine behind European market growth.
It’s now five months since the German Federal Cabinet adopted draft amendments to its pivotal Medizinal-Cannabisgesetzes (MedCanG) bill, and its finalisation is expected in the coming weeks.
Germany’s cannabis imports, according to the latest figures from BfArM, nearly tripled in size in 2025, cementing it beyond any doubt as the engine behind Europe’s medical cannabis boom.
Last month (January 15, 2026) Germany’s Bundesrag held a debate on the hotly contested amendments aimed at significantly restricting medical cannabis prescriptions, and potentially transforming the industry.
Today, (Wednesday, January 14), a public hearing will bring together 22 hand-picked experts for a debate on the future country’s near-billion-euro medical cannabis industry.
As Trump’s rescheduling executive order dominated the cannabis industry’s attention over the holiday period, Germany’s controversial medical cannabis bill quietly entered its most critical phase.
